Actively Recruiting
Treatable Traits in Interstitial Lung Disease
Led by The University of Western Australia · Updated on 2025-10-07
110
Participants Needed
2
Research Sites
95 weeks
Total Duration
On this page
Sponsors
T
The University of Western Australia
Lead Sponsor
F
Fiona Stanley Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if a personalised treatment model of care "treatable traits" can improve quality of life and disease progression in patients with interstitial lung disease. The main question it aims to answer is, will providing a treatable traits model of care improve health-related quality of life (HRQoL) (primary outcome), symptoms, anxiety, physical activity, and body composition (secondary outcomes). Researchers will compare the treatable traits model to standard of care. Participants in both arms will complete surveys, a Dual-Energy X-Ray Absorptiometry (DEXA) and whole-body composition scan, lung function and blood tests. Those in the intervention (TT) arm will be seen in a multidisciplinary clinic where they are seen by an ILD doctor, physiotherapist, psychologist, and dietitian.
CONDITIONS
Official Title
Treatable Traits in Interstitial Lung Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older with a confirmed diagnosis of fibrotic interstitial lung disease by an ILD multidisciplinary team
- Diagnosis includes all ILD subtypes except sarcoidosis
- Receiving care at Fiona Stanley Hospital or Sir Charles Gairdner Hospital ILD service
- Able to provide consent
- On stable ILD treatment for at least 1 month before starting the study
You will not qualify if you...
- Experienced an acute exacerbation of ILD within 4 weeks prior to study start
- Expected to require lung transplant or likely to die during the study period
- Active suicidality, severe depression, psychosis, mania, or other severe psychiatric conditions requiring more intensive treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia, 6009
Not Yet Recruiting
2
Fiona Stanley Hospital
Perth, Western Australia, Australia, 6150
Actively Recruiting
Research Team
M
Megan Harrison, MBSS (Hons) FRACP
CONTACT
Y
Yuben Moodley, MBSS, FRACP, MD, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here